Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teplizumab long-term extension in recent-onset type 1 diabetes
2008-008432-82Phase 3Terminated
- Sponsor
- MacroGenics
- Start
- May 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of teplizumab in diabetes mellitus type 1 (T1D), sponsored by MacroGenics. Primary endpoint: Safety endpoints. Started May 2009; status: terminated.
02
Drugs
teplizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2008-008432-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008432-82.